169 related articles for article (PubMed ID: 28666368)
1. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Qian Y; Maruyama S; Kim H; Pollom EL; Kumar KA; Chin AL; Harris JP; Chang DT; Pitt A; Bendavid E; Owens DK; Durkee BY; Soltys SG
Neuro Oncol; 2017 Nov; 19(12):1651-1660. PubMed ID: 28666368
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Shaw EG; Wang M; Coons SW; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2012 Sep; 30(25):3065-70. PubMed ID: 22851558
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
5. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
[TBL] [Abstract][Full Text] [Related]
6. One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Keogh RJ; Aslam R; Hennessy MA; Coyne Z; Hennessy BT; Breathnach OS; Grogan L; Morris PG
BMC Cancer; 2021 Feb; 21(1):140. PubMed ID: 33557783
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
[TBL] [Abstract][Full Text] [Related]
8. Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Prabhu RS; Won M; Shaw EG; Hu C; Brachman DG; Buckner JC; Stelzer KJ; Barger GR; Brown PD; Gilbert MR; Mehta MP
J Clin Oncol; 2014 Feb; 32(6):535-41. PubMed ID: 24419119
[TBL] [Abstract][Full Text] [Related]
9. Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
van den Bent MJ
Neuro Oncol; 2014 Dec; 16(12):1570-4. PubMed ID: 25355680
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Intraoperative MRI for Treatment of High-Grade Gliomas.
Abraham P; Sarkar R; Brandel MG; Wali AR; Rennert RC; Lopez Ramos C; Padwal J; Steinberg JA; Santiago-Dieppa DR; Cheung V; Pannell JS; Murphy JD; Khalessi AA
Radiology; 2019 Jun; 291(3):689-697. PubMed ID: 30912721
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Martikainen JA; Kivioja A; Hallinen T; Vihinen P
Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of preoperative motor mapping with navigated transcranial magnetic brain stimulation in patients with high-grade glioma.
Butenschön VM; Ille S; Sollmann N; Meyer B; Krieg SM
Neurosurg Focus; 2018 Jun; 44(6):E18. PubMed ID: 29852777
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
Medical Research Council Brain Tumor Working Party
J Clin Oncol; 2001 Jan; 19(2):509-18. PubMed ID: 11208845
[TBL] [Abstract][Full Text] [Related]
14. A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic Acid compared with white-light surgery.
Esteves S; Alves M; Castel-Branco M; Stummer W
Neurosurgery; 2015 May; 76(5):552-62; discussion 562. PubMed ID: 25714513
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
[TBL] [Abstract][Full Text] [Related]
16. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Kovic B; Xie F
J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
[TBL] [Abstract][Full Text] [Related]
17. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
Prados MD; Scott C; Sandler H; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1109-15. PubMed ID: 10613302
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
19. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
[TBL] [Abstract][Full Text] [Related]
20. Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Mazzocco P; Honnorat J; Ducray F; Ribba B
Comput Math Methods Med; 2015; 2015():297903. PubMed ID: 26788118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
